Since 2002 Biopta has been a provider of fresh functional human tissues to the pharmaceutical industry, for the better prediction of drug activity prior to clinical trials. Biopta brings to the ReproCELL Group expertise in all areas of human tissues research including sourcing, handling and experimenting on human tissue.
Dr David Bunton, Biopta’s co-founder and CEO said, “The acquisition by ReproCELL is a great opportunity to build on the solid platform we have in outsourced drug discovery services. Scotland is known for the quality of its scientists and customer service and ReproCELL’s investment recognizes these strengths. We have had a close partnership with BioServe, another ReproCELL Group company, for the past five years, which has helped us establish a very successful US subsidiary. We see the acquisition as the natural next step in the growth of the UK and US businesses.”